Based on the above findings and our previous TORCH study, the treatment approach of combining PD-1 monotherapy with SCRT and chemotherapy is expected to remarkably improve tumour regression and CR rate, and provide more options for patients with early rectal cancer to achieve organ preservation. The gene discussed is PDCD1; the disease is rectal cancer.